MWG Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - InMed Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 1.14 EUR -3.39% Market Closed

Market Cap: €18.5m

I	InMed Pharmaceuticals Inc F:MWG	CA
N	Nektar Therapeutics F:ITH	US
V	Vitasoy International Holdings Ltd XMUN:VS6	HK

Profitability Summary

InMed Pharmaceuticals Inc's profitability score is 4/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Sustainable 3Y Average Gross Margin

29%

Negative Operating Margin

-263%

Negative 3Y Average Operating Margin

-181%

Declining Operating Margin

-203% > -263%

Negative Net Margin

-262%

Negative 3Y Average Net Margin

-178%

Declining Net Margin

-192% > -262%

Negative Free Cash Flow Margin

-230%

Negative 3Y Average Free Cash Flow Margin

-168%

Declining Free Cash Flow Margin

-180% > -230%

Negative ROE

-122%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-176%

Declining ROIC

-168% > -222%

View All

Hide

Collapse

4 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.